Plain-English translation of NCT04152993 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a device called Responsive Neurostimulation (RNS) that is implanted in the brain to help treat severe post-traumatic stress disorder (PTSD) that hasn't improved with standard treatments. The device records brain activity and delivers small electrical pulses to a specific brain region involved in fear and anxiety when it detects patterns linked to PTSD symptoms like flashbacks and nightmares. The goal is to help veterans whose PTSD has not responded to medications or therapy feel better and function more fully.
Standard treatments for PTSD—including medications and talk therapy—don't work for everyone, leaving some people with severe, ongoing symptoms that significantly interfere with their daily lives. This trial exists to test whether a device that directly targets the brain circuits involved in fear processing can help people who haven't benefited from other treatments.
You likely qualify if…
You likely don't qualify if…
You would undergo brain surgery to have the RNS device implanted in the area of your brain involved in fear and emotion. After implantation, the device would record your brain activity and be programmed to detect patterns related to your specific PTSD symptoms. You would have regular appointments over 4 years to adjust the device settings, complete psychological assessments and questionnaires, and undergo brain imaging and monitoring tests to track how the treatment is working.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States